HemaCare Corporation announced their involvement as a provider of leukapheresis process development material for 100% of the current FDA-approved immunocellular therapies, Kymriah® (Novartis; Switzerland), Yescarta®, and Provenge®. During the development process, HemaCare worked collaboratively with each company to source healthy donors per project requirements. All leukapheresis material was collected and shipped following stringent standards as developed by the AABB and accepted by the FDA. In some cases, HemaCare performed further processing by splitting collections for comparability runs, freezing material, or adding isolated cells to mimic patient collection material. Industry cell therapy thought-leaders rely heavily on HemaCare’s extensive and recallable donor database. “While at Novartis, Biogen, and now Mustang, HemaCare has provided high-quality leukapheresis starting material for process development work.